HAEEПептид HAEE
What the studies found
Human biomarker study · no treatment tested · 2026
Plasma HAEE in Alzheimer’s disease and healthy controls
- Median plasma HAEE
- 143.1 pg/mL in Alzheimer’s cases versus 285.0 pg/mL in healthy controls.
- ROC discrimination
- AUC 0.832 (p<0.001), with 84.13% sensitivity and 63.51% specificity at the study cut-off.
143.1 pg/mL in Alzheimer’s cases versus 285.0 pg/mL in healthy controls.
Study notes · methods, sources and limitations
Participants or model 200 patients with a clinical Alzheimer’s diagnosis and 150 healthy controls
Design Cross-sectional LC–MS/MS plasma measurements. Table 1 and Figure 1 report group distributions and ROC analysis.
Important limitations
- The assay needs independent validation against other causes of cognitive impairment. The authors disclose related patent interests. The study did not administer HAEE.
PNAS Nexus · Journal publication
Animal research · 2025
HAEE and amyloid-β clearance in mice and cell assays
- Brain amyloid-β and IL-6
- 35% lower amyloid-β and 40% lower IL-6 with HAEE.
- Brain TNF-α
- No change with HAEE.
- Microglial amyloid degradation
- Approximately 2× the degradation rate in a separate cell experiment.
35% lower amyloid-β and 40% lower IL-6 with HAEE.
Study notes · methods, sources and limitations
Participants or model Mouse acute amyloid challenge, primary brain cultures and a transwell barrier model
Design The authors measured brain homogenates three days after intracerebroventricular oligomeric amyloid-β injection and a course of HAEE. Figure 1 lists n=8 for the brain measurements.
Important limitations
- This acute experimental challenge and the cell assays address clearance mechanisms. Clinical effects remain unknown.
International Journal of Molecular Sciences · Journal publication
Animal research · 2023
Zinc-dependent amyloid-β aggregation and HAEE
- Zinc-dependent amyloid pathology
- HAEE reversed the extra amyloid accumulation, paralysis and lifespan shortening induced by isomerized amyloid-β with zinc in the nematode model.
HAEE reversed the extra amyloid accumulation, paralysis and lifespan shortening induced by isomerized amyloid-β with zinc in the nematode model.
Study notes · methods, sources and limitations
Participants or model Transgenic nematodes expressing human amyloid-β and molecular assays
Design The investigators combined molecular binding assays with a transgenic nematode model to test the interaction between zinc, isomerized amyloid-β and HAEE.
Important limitations
- The findings apply to molecular and nematode experiments.
Aging and Disease · Journal publication
About HAEE
Names in this research collection
His-Ala-Glu-Glu · Ac-His-Ala-Glu-Glu-NH₂
HAEE is Ac-His-Ala-Glu-Glu-NH₂. Studies examine zinc-dependent amyloid aggregation, experimental clearance and plasma concentrations in people with Alzheimer’s disease.
Research background
HAEE is Ac-His-Ala-Glu-Glu-NH₂. Studies examine zinc-dependent amyloid aggregation, experimental clearance and plasma concentrations in people with Alzheimer’s disease.
Alzheimer’s research evidence map ↗
- Compound class
- Synthetic tetrapeptide
- Research collection
- Neuropeptide research · editorial grouping
- Research institutions
- No institutional affiliation recorded
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
One observational biomarker cohort. Human treatment effects remain uncharacterized.
Study methods
Mass spectrometry, molecular assays, mouse and cell models, and patent examples.
Independent replication
The plasma result needs independent validation.
Source access
Original articles and Russian patents.
Safety evidence
Human treatment safety remains uncharacterized.
Open a topic for the evidence assessment.
More findings, background and history
What remains unclear
Group assignment, comparators, planned outcomes, effect estimates, adverse events and possible participant overlap are key limits to interpreting the studies.
Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.
Browse original study records ↗Patents and claimed inventions
These 10 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
2019 · RU2709539C1 · HAEE–zinc–albumin formulationFormulation · Approximately 2× the half-life and 5× the apparent brain distribution compared with unformulated HAEE.
Reported findings
Approximately 2× the half-life and 5× the apparent brain distribution compared with unformulated HAEE.
- Elimination half-life and brain distribution
- Approximately 2× the half-life and 5× the apparent brain distribution compared with unformulated HAEE.
Formulation. Claims a composition of HAEE, zinc ions and human serum albumin.
These estimates apply to the albumin formulation in the mouse comparison. The preparation differs from the binary zinc complex and the PGP-extended peptide.
- Publication
- RU2709539C1 ↗ · 2019-12-18
- Earliest priority / filing
- 2019-08-15 / 2019-08-15
- Original applicant / assignee
- VladMiVa experimental plant
- Indexed status
- Not shown; official status unverified · checked 2026-11-12
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
HAEE–zinc–albumin formulation
Inventors: Sergey A. Kozin; Alexander O. Morozov; Vladimir P. Chuev; Andrey A. Buzov; Valentina S. Kazakova.
2022 · RU2784249C1 · HAEE ammonium saltsFormulation · The disclosure reports preserved active content for the ammonium salts within assay precision. Unformulated HAEE fell to 67.4%.
Reported findings
The disclosure reports preserved active content for the ammonium salts within assay precision. Unformulated HAEE fell to 67.4%.
- Six-month accelerated storage
- The disclosure reports preserved active content for the ammonium salts within assay precision. Unformulated HAEE fell to 67.4%.
Formulation. Claims mono- and disubstituted ammonium salts of HAEE and their preparations.
These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
- Publication
- RU2784249C1 ↗ · 2022-11-23
- Earliest priority / filing
- 2022-07-15 / 2022-07-15
- Original applicant / assignee
- Lifemission LLC
- Indexed status
- Not shown; official status unverified · checked 2026-11-12
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
HAEE ammonium salts
Inventors: Sergey A. Kozin.
2022 · RU2784326C1 · HAEE sodium saltsFormulation · 99.3% for monosodium HAEE, 99.2% for disodium HAEE and 67.4% for unformulated HAEE (Table 2).
Reported findings
99.3% for monosodium HAEE, 99.2% for disodium HAEE and 67.4% for unformulated HAEE (Table 2).
- Active content at six months
- 99.3% for monosodium HAEE, 99.2% for disodium HAEE and 67.4% for unformulated HAEE (Table 2).
Formulation. Claims mono- and disubstituted sodium salts of HAEE and their preparations.
These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
- Publication
- RU2784326C1 ↗ · 2022-11-23
- Earliest priority / filing
- 2022-07-15 / 2022-07-15
- Original applicant / assignee
- Lifemission LLC
- Indexed status
- Not shown; official status unverified · checked 2026-11-12
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
HAEE sodium salts
Inventors: Sergey A. Kozin.
2022 · RU2784319C1 · HAEE zinc complexFormulation · Selected Table 3 values were 99.4% for the acetate, 100.1% for the sulfate and 99.9% for the chloride.
Reported findings
Selected Table 3 values were 99.4% for the acetate, 100.1% for the sulfate and 99.9% for the chloride.
- Active content at six months
- Selected Table 3 values were 99.4% for the acetate, 100.1% for the sulfate and 99.9% for the chloride.
Formulation. Claims zinc–HAEE complexes with specified pharmaceutically acceptable anions.
These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
- Publication
- RU2784319C1 ↗ · 2022-11-23
- Earliest priority / filing
- 2022-07-15 / 2022-07-15
- Original applicant / assignee
- Lifemission LLC
- Indexed status
- Not shown; official status unverified · checked 2026-11-12
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
HAEE zinc complex
Inventors: Sergey A. Kozin.
2022 · RU2784732C1 · HAEE copper complexFormulation · Selected Table 3 values were 99.1% for the acetate, 99.9% for the sulfate and 99.2% for the chloride.
Reported findings
Selected Table 3 values were 99.1% for the acetate, 99.9% for the sulfate and 99.2% for the chloride.
- Active content at six months
- Selected Table 3 values were 99.1% for the acetate, 99.9% for the sulfate and 99.2% for the chloride.
Formulation. Claims copper–HAEE complexes and related pharmaceutical preparations.
These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
- Publication
- RU2784732C1 ↗ · 2022-11-29
- Earliest priority / filing
- 2022-07-15 / 2022-07-15
- Original applicant / assignee
- Lifemission LLC
- Indexed status
- Not shown; official status unverified · checked 2026-11-12
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
HAEE copper complex
Inventors: Sergey A. Kozin.
2022 · RU2784746C1 · HAEE magnesium complexFormulation · The magnesium complex showed a higher melting temperature than HAEE. The disclosure reports improved stability in the accelerated storage test.
Reported findings
The magnesium complex showed a higher melting temperature than HAEE. The disclosure reports improved stability in the accelerated storage test.
- Thermal behavior and storage
- The magnesium complex showed a higher melting temperature than HAEE. The disclosure reports improved stability in the accelerated storage test.
Formulation. Claims magnesium–HAEE complexes. The original Russian text identifies magnesium as the metal.
These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
- Publication
- RU2784746C1 ↗ · 2022-11-29
- Earliest priority / filing
- 2022-07-15 / 2022-07-15
- Original applicant / assignee
- Lifemission LLC
- Indexed status
- Not shown; official status unverified · checked 2026-11-12
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
HAEE magnesium complex
Inventors: Sergey A. Kozin.
2022 · RU2785354C1 · HAEE calcium complexFormulation · Selected Table 3 values were 99.4% for the acetate, 99.8% for the dihydrogen phosphate and 99.3% for the chloride.
Reported findings
Selected Table 3 values were 99.4% for the acetate, 99.8% for the dihydrogen phosphate and 99.3% for the chloride.
- Active content at six months
- Selected Table 3 values were 99.4% for the acetate, 99.8% for the dihydrogen phosphate and 99.3% for the chloride.
Formulation. Claims calcium–HAEE complexes and related pharmaceutical preparations.
These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
- Publication
- RU2785354C1 ↗ · 2022-12-06
- Earliest priority / filing
- 2022-07-15 / 2022-07-15
- Original applicant / assignee
- Lifemission LLC
- Indexed status
- Not shown; official status unverified · checked 2026-11-12
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
HAEE calcium complex
Inventors: Sergey A. Kozin.
2024 · RU2822603C1 · HAEE and derivatives in neuronal function researchUse · Approximately 100 pg/mL over 30 days in the cited cell culture example.
Reported findings
Approximately 100 pg/mL over 30 days in the cited cell culture example.
- Reported secreted factor in culture medium
- Approximately 100 pg/mL over 30 days in the cited cell culture example.
Use. Claims HAEE and specified derivative preparations for neuronal function recovery.
The culture result measures a reported secreted factor. It does not establish recovery in patients or identify the exact HAEEPGP sequence as a tested preparation.
- Publication
- RU2822603C1 ↗ · 2024-07-09
- Earliest priority / filing
- 2023-03-03 / 2023-03-03
- Original applicant / assignee
- Lifemission LLC
- Indexed status
- Not shown; official status unverified · checked 2026-11-12
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
HAEE and derivatives in neuronal function research
Inventors: Sergey A. Kozin; Artur T. Kopylov; Evgeniya M. Karpova; Ruslan Y. Yakovlev.
2025 · RU2841374C1 · HAEE and derivatives for proposed endogenous HAEE deficiencyUse · The patent reports about twice the endogenous HAEE concentration in the active groups as in saline controls, alongside behavioral differences (Tables 2–3).
Reported findings
The patent reports about twice the endogenous HAEE concentration in the active groups as in saline controls, alongside behavioral differences (Tables 2–3).
- Endogenous HAEE at day 30
- The patent reports about twice the endogenous HAEE concentration in the active groups as in saline controls, alongside behavioral differences (Tables 2–3).
Use. Claims HAEE, salts and complexes for conditions the filing associates with lower endogenous HAEE.
This is a small post-stroke rat experiment among selected survivors. The filing does not establish an Alzheimer’s treatment effect.
- Publication
- RU2841374C1 ↗ · 2025-06-06
- Earliest priority / filing
- 2025-03-14 / 2025-03-14
- Original applicant / assignee
- Sergey A. Kozin
- Indexed status
- Not shown; official status unverified · checked 2026-11-12
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
HAEE and derivatives for proposed endogenous HAEE deficiency
Inventors: Sergey A. Kozin; Artur T. Kopylov; Ruslan Y. Yakovlev; Evgeny V. Myachin.
2025 · RU2851848C1 · Amino acid–zinc–HAEE complexesFormulation · Table 3 reports chemical shift changes for glycine–zinc–HAEE and methionine–zinc–HAEE compared with their free components.
Reported findings
Table 3 reports chemical shift changes for glycine–zinc–HAEE and methionine–zinc–HAEE compared with their free components.
- Proton NMR
- Table 3 reports chemical shift changes for glycine–zinc–HAEE and methionine–zinc–HAEE compared with their free components.
Formulation. Claims complexes of an individual amino acid, zinc and the HAEE tetrapeptide.
The NMR comparison characterizes complex formation. An amino acid coordinated to zinc and HAEE differs from a covalently extended peptide.
- Publication
- RU2851848C1 ↗ · 2025-12-01
- Earliest priority / filing
- 2025-03-14 / 2025-03-14
- Original applicant / assignee
- Serafim Consumer Cooperative
- Indexed status
- Not shown; official status unverified · checked 2026-11-12
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
Amino acid–zinc–HAEE complexes
Inventors: Sergey A. Kozin; Artur T. Kopylov; Ruslan Y. Yakovlev; Evgeny V. Myachin.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Linked sources
Explore the research map and unresolved leads ↗
2019 · HAEE–zinc–albumin formulation — RU2709539C1Elimination half-life and brain distribution: Approximately 2× the half-life and 5× the apparent brain distribution compared with unformulated HAEE.
HAEE–zinc–albumin formulation — RU2709539C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Sergey A. Kozin, Alexander O. Morozov, Vladimir P. Chuev, Andrey A. Buzov, Valentina S. Kazakova · RU2709539C1 · patent family RU2709539C1
Approximately 2× the half-life and 5× the apparent brain distribution compared with unformulated HAEE.
Results and tables
Reported patent results
Reported findings
Approximately 2× the half-life and 5× the apparent brain distribution compared with unformulated HAEE.
Example 3 and Table 6 compare the formulation with unformulated HAEE after a single 0.05 mg/kg intraperitoneal dose (HAEE equivalent) in C57BL/6 mice. The example lists N=36.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Elimination half-life and brain distribution | Approximately 2× the half-life and 5× the apparent brain distribution compared with unformulated HAEE. |
These estimates apply to the albumin formulation in the mouse comparison. The preparation differs from the binary zinc complex and the PGP-extended peptide.
Source for these results ↗ · Reviewed 2026-11-12
- Population / setting
- Example 3 and Table 6 compare the formulation with unformulated HAEE after a single 0.05 mg/kg intraperitoneal dose (HAEE equivalent) in C57BL/6 mice. The example lists N=36.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- These estimates apply to the albumin formulation in the mouse comparison. The preparation differs from the binary zinc complex and the PGP-extended peptide.
- These estimates apply to the albumin formulation in the mouse comparison. The preparation differs from the binary zinc complex and the PGP-extended peptide.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-12.
2022 · HAEE ammonium salts — RU2784249C1Six-month accelerated storage: The disclosure reports preserved active content for the ammonium salts within assay precision. Unformulated HAEE fell to 67.4%.
HAEE ammonium salts — RU2784249C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Sergey A. Kozin · RU2784249C1 · patent family RU2784249C1
The disclosure reports preserved active content for the ammonium salts within assay precision. Unformulated HAEE fell to 67.4%.
Results and tables
Reported patent results
Reported findings
The disclosure reports preserved active content for the ammonium salts within assay precision. Unformulated HAEE fell to 67.4%.
HPLC measurement of active content after accelerated storage for six months at 40 °C and 75% relative humidity. Reported analytical error was 1%.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Six-month accelerated storage | The disclosure reports preserved active content for the ammonium salts within assay precision. Unformulated HAEE fell to 67.4%. |
These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
Source for these results ↗ · Reviewed 2026-11-12
- Population / setting
- HPLC measurement of active content after accelerated storage for six months at 40 °C and 75% relative humidity. Reported analytical error was 1%.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
- These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-12.
2022 · HAEE sodium salts — RU2784326C1Active content at six months: 99.3% for monosodium HAEE, 99.2% for disodium HAEE and 67.4% for unformulated HAEE (Table 2).
HAEE sodium salts — RU2784326C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Sergey A. Kozin · RU2784326C1 · patent family RU2784326C1
99.3% for monosodium HAEE, 99.2% for disodium HAEE and 67.4% for unformulated HAEE (Table 2).
Results and tables
Reported patent results
Reported findings
99.3% for monosodium HAEE, 99.2% for disodium HAEE and 67.4% for unformulated HAEE (Table 2).
HPLC measurement of active content after accelerated storage for six months at 40 °C and 75% relative humidity. Reported analytical error was 1%.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Active content at six months | 99.3% for monosodium HAEE, 99.2% for disodium HAEE and 67.4% for unformulated HAEE (Table 2). |
These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
Source for these results ↗ · Reviewed 2026-11-12
- Population / setting
- HPLC measurement of active content after accelerated storage for six months at 40 °C and 75% relative humidity. Reported analytical error was 1%.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
- These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-12.
2022 · HAEE zinc complex — RU2784319C1Active content at six months: Selected Table 3 values were 99.4% for the acetate, 100.1% for the sulfate and 99.9% for the chloride.
HAEE zinc complex — RU2784319C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Sergey A. Kozin · RU2784319C1 · patent family RU2784319C1
Selected Table 3 values were 99.4% for the acetate, 100.1% for the sulfate and 99.9% for the chloride.
Results and tables
Reported patent results
Reported findings
Selected Table 3 values were 99.4% for the acetate, 100.1% for the sulfate and 99.9% for the chloride.
HPLC measurement of active content after accelerated storage for six months at 40 °C and 75% relative humidity. Reported analytical error was 1%.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Active content at six months | Selected Table 3 values were 99.4% for the acetate, 100.1% for the sulfate and 99.9% for the chloride. |
These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
Source for these results ↗ · Reviewed 2026-11-12
- Population / setting
- HPLC measurement of active content after accelerated storage for six months at 40 °C and 75% relative humidity. Reported analytical error was 1%.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
- These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-12.
2022 · HAEE copper complex — RU2784732C1Active content at six months: Selected Table 3 values were 99.1% for the acetate, 99.9% for the sulfate and 99.2% for the chloride.
HAEE copper complex — RU2784732C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Sergey A. Kozin · RU2784732C1 · patent family RU2784732C1
Selected Table 3 values were 99.1% for the acetate, 99.9% for the sulfate and 99.2% for the chloride.
Results and tables
Reported patent results
Reported findings
Selected Table 3 values were 99.1% for the acetate, 99.9% for the sulfate and 99.2% for the chloride.
HPLC measurement of active content after accelerated storage for six months at 40 °C and 75% relative humidity. Reported analytical error was 1%.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Active content at six months | Selected Table 3 values were 99.1% for the acetate, 99.9% for the sulfate and 99.2% for the chloride. |
These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
Source for these results ↗ · Reviewed 2026-11-12
- Population / setting
- HPLC measurement of active content after accelerated storage for six months at 40 °C and 75% relative humidity. Reported analytical error was 1%.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
- These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-12.
2022 · HAEE magnesium complex — RU2784746C1Thermal behavior and storage: The magnesium complex showed a higher melting temperature than HAEE. The disclosure reports improved stability in the accelerated storage test.
HAEE magnesium complex — RU2784746C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Sergey A. Kozin · RU2784746C1 · patent family RU2784746C1
The magnesium complex showed a higher melting temperature than HAEE. The disclosure reports improved stability in the accelerated storage test.
Results and tables
Reported patent results
Reported findings
The magnesium complex showed a higher melting temperature than HAEE. The disclosure reports improved stability in the accelerated storage test.
The patent uses differential scanning calorimetry and accelerated storage to compare the complex with HAEE.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Thermal behavior and storage | The magnesium complex showed a higher melting temperature than HAEE. The disclosure reports improved stability in the accelerated storage test. |
These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
Source for these results ↗ · Reviewed 2026-11-12
- Population / setting
- The patent uses differential scanning calorimetry and accelerated storage to compare the complex with HAEE.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
- These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-12.
2022 · HAEE calcium complex — RU2785354C1Active content at six months: Selected Table 3 values were 99.4% for the acetate, 99.8% for the dihydrogen phosphate and 99.3% for the chloride.
HAEE calcium complex — RU2785354C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Sergey A. Kozin · RU2785354C1 · patent family RU2785354C1
Selected Table 3 values were 99.4% for the acetate, 99.8% for the dihydrogen phosphate and 99.3% for the chloride.
Results and tables
Reported patent results
Reported findings
Selected Table 3 values were 99.4% for the acetate, 99.8% for the dihydrogen phosphate and 99.3% for the chloride.
HPLC measurement of active content after accelerated storage for six months at 40 °C and 75% relative humidity. Reported analytical error was 1%.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Active content at six months | Selected Table 3 values were 99.4% for the acetate, 99.8% for the dihydrogen phosphate and 99.3% for the chloride. |
These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
Source for these results ↗ · Reviewed 2026-11-12
- Population / setting
- HPLC measurement of active content after accelerated storage for six months at 40 °C and 75% relative humidity. Reported analytical error was 1%.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
- These are accelerated storage and chemical characterization results for a specified HAEE preparation. Clinical effects and HAEEPGP stability were outside the experiment.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-12.
2024 · HAEE and derivatives in neuronal function research — RU2822603C1Reported secreted factor in culture medium: Approximately 100 pg/mL over 30 days in the cited cell culture example.
HAEE and derivatives in neuronal function research — RU2822603C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Sergey A. Kozin, Artur T. Kopylov, Evgeniya M. Karpova, Ruslan Y. Yakovlev · RU2822603C1 · patent family RU2822603C1
Approximately 100 pg/mL over 30 days in the cited cell culture example.
Results and tables
Reported patent results
Reported findings
Approximately 100 pg/mL over 30 days in the cited cell culture example.
In a human induced pluripotent stem cell-derived neuron and astrocyte culture, the authors measured the reported secreted factor by HPLC–MS in conditioned medium.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported secreted factor in culture medium | Approximately 100 pg/mL over 30 days in the cited cell culture example. |
The culture result measures a reported secreted factor. It does not establish recovery in patients or identify the exact HAEEPGP sequence as a tested preparation.
Source for these results ↗ · Reviewed 2026-11-12
- Population / setting
- In a human induced pluripotent stem cell-derived neuron and astrocyte culture, the authors measured the reported secreted factor by HPLC–MS in conditioned medium.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The culture result measures a reported secreted factor. It does not establish recovery in patients or identify the exact HAEEPGP sequence as a tested preparation.
- The culture result measures a reported secreted factor. It does not establish recovery in patients or identify the exact HAEEPGP sequence as a tested preparation.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-12.
2025 · HAEE and derivatives for proposed endogenous HAEE deficiency — RU2841374C1Endogenous HAEE at day 30: The patent reports about twice the endogenous HAEE concentration in the active groups as in saline controls, alongside behavioral differences (Tables 2–3).
HAEE and derivatives for proposed endogenous HAEE deficiency — RU2841374C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Sergey A. Kozin, Artur T. Kopylov, Ruslan Y. Yakovlev, Evgeny V. Myachin · RU2841374C1 · patent family RU2841374C1
The patent reports about twice the endogenous HAEE concentration in the active groups as in saline controls, alongside behavioral differences (Tables 2–3).
Results and tables
Reported patent results
Reported findings
The patent reports about twice the endogenous HAEE concentration in the active groups as in saline controls, alongside behavioral differences (Tables 2–3).
A rat stroke example enrolled 80 rats before surgery, reported 23 survivors on day 10 and formed four groups of five. The patent describes eight intraperitoneal injections of 0.3 mg/kg HAEE equivalent or saline.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Endogenous HAEE at day 30 | The patent reports about twice the endogenous HAEE concentration in the active groups as in saline controls, alongside behavioral differences (Tables 2–3). |
This is a small post-stroke rat experiment among selected survivors. The filing does not establish an Alzheimer’s treatment effect.
Source for these results ↗ · Reviewed 2026-11-12
- Population / setting
- A rat stroke example enrolled 80 rats before surgery, reported 23 survivors on day 10 and formed four groups of five. The patent describes eight intraperitoneal injections of 0.3 mg/kg HAEE equivalent or saline.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- This is a small post-stroke rat experiment among selected survivors. The filing does not establish an Alzheimer’s treatment effect.
- This is a small post-stroke rat experiment among selected survivors. The filing does not establish an Alzheimer’s treatment effect.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-12.
2025 · Amino acid–zinc–HAEE complexes — RU2851848C1Proton NMR: Table 3 reports chemical shift changes for glycine–zinc–HAEE and methionine–zinc–HAEE compared with their free components.
Amino acid–zinc–HAEE complexes — RU2851848C1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Sergey A. Kozin, Artur T. Kopylov, Ruslan Y. Yakovlev, Evgeny V. Myachin · RU2851848C1 · patent family RU2851848C1
Table 3 reports chemical shift changes for glycine–zinc–HAEE and methionine–zinc–HAEE compared with their free components.
Results and tables
Reported patent results
Reported findings
Table 3 reports chemical shift changes for glycine–zinc–HAEE and methionine–zinc–HAEE compared with their free components.
The patent reports NMR chemical shifts for HAEE, free amino acids and their complexes in solution.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Proton NMR | Table 3 reports chemical shift changes for glycine–zinc–HAEE and methionine–zinc–HAEE compared with their free components. |
The NMR comparison characterizes complex formation. An amino acid coordinated to zinc and HAEE differs from a covalently extended peptide.
Source for these results ↗ · Reviewed 2026-11-12
- Population / setting
- The patent reports NMR chemical shifts for HAEE, free amino acids and their complexes in solution.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The NMR comparison characterizes complex formation. An amino acid coordinated to zinc and HAEE differs from a covalently extended peptide.
- The NMR comparison characterizes complex formation. An amino acid coordinated to zinc and HAEE differs from a covalently extended peptide.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-12.
2026 · Plasma HAEE in Alzheimer’s disease and healthy controlsMedian plasma HAEE: 143.1 pg/mL in Alzheimer’s cases versus 285.0 pg/mL in healthy controls.
Plasma HAEE in Alzheimer’s disease and healthy controls
· Journal publication
Kopylov AT, Kozin SA · PNAS Nexus
143.1 pg/mL in Alzheimer’s cases versus 285.0 pg/mL in healthy controls.
Results and tables
Reported findings and study design
Cross-sectional LC–MS/MS plasma measurements. Table 1 and Figure 1 report group distributions and ROC analysis.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Median plasma HAEE | 143.1 pg/mL in Alzheimer’s cases versus 285.0 pg/mL in healthy controls. | |
| ROC discrimination | AUC 0.832 (p<0.001), with 84.13% sensitivity and 63.51% specificity at the study cut-off. |
The assay needs independent validation against other causes of cognitive impairment. The authors disclose related patent interests. The study did not administer HAEE.
Source for these results ↗ · Reviewed 2026-11-12
- Population / setting
- 200 patients with a clinical Alzheimer’s diagnosis and 150 healthy controls
- Source reviewed
- Original full text checked for selected methods and findings.
Study limitations
- The assay needs independent validation against other causes of cognitive impairment. The authors disclose related patent interests. The study did not administer HAEE.
Reviewed 2026-11-12.
2025 · HAEE and amyloid-β clearance in mice and cell assaysBrain amyloid-β and IL-6: 35% lower amyloid-β and 40% lower IL-6 with HAEE.
HAEE and amyloid-β clearance in mice and cell assays
· Journal publication
Mukhina KA, Varshavskaya KB, Rybak AD, Grishchenko VV, Kuzubova EV, Korokin MV, Kechko OI, Mitkevich VA · International Journal of Molecular Sciences
35% lower amyloid-β and 40% lower IL-6 with HAEE.
Results and tables
Reported findings and study design
The authors measured brain homogenates three days after intracerebroventricular oligomeric amyloid-β injection and a course of HAEE. Figure 1 lists n=8 for the brain measurements.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Brain amyloid-β and IL-6 | 35% lower amyloid-β and 40% lower IL-6 with HAEE. | |
| Brain TNF-α | No change with HAEE. | |
| Microglial amyloid degradation | Approximately 2× the degradation rate in a separate cell experiment. |
This acute experimental challenge and the cell assays address clearance mechanisms. Clinical effects remain unknown.
Source for these results ↗ · Reviewed 2026-11-12
- Population / setting
- Mouse acute amyloid challenge, primary brain cultures and a transwell barrier model
- Source reviewed
- Original full text checked for selected methods and findings.
Study limitations
- This acute experimental challenge and the cell assays address clearance mechanisms. Clinical effects remain unknown.
Reviewed 2026-11-12.
2023 · Zinc-dependent amyloid-β aggregation and HAEEZinc-dependent amyloid pathology: HAEE reversed the extra amyloid accumulation, paralysis and lifespan shortening induced by isomerized amyloid-β with zinc in the nematode model.
Zinc-dependent amyloid-β aggregation and HAEE
· Journal publication
Mitkevich VA, Barykin EP, Eremina SY · Aging and Disease
HAEE reversed the extra amyloid accumulation, paralysis and lifespan shortening induced by isomerized amyloid-β with zinc in the nematode model.
Results and tables
Reported findings and study design
The investigators combined molecular binding assays with a transgenic nematode model to test the interaction between zinc, isomerized amyloid-β and HAEE.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Zinc-dependent amyloid pathology | HAEE reversed the extra amyloid accumulation, paralysis and lifespan shortening induced by isomerized amyloid-β with zinc in the nematode model. |
The findings apply to molecular and nematode experiments.
Source for these results ↗ · Reviewed 2026-11-12
- Population / setting
- Transgenic nematodes expressing human amyloid-β and molecular assays
- Source reviewed
- Original full text checked for selected methods and findings.
Study limitations
- The findings apply to molecular and nematode experiments.
Reviewed 2026-11-12.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗